{"id":417619,"date":"2021-01-20T07:03:25","date_gmt":"2021-01-20T12:03:25","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=417619"},"modified":"2021-01-20T07:03:25","modified_gmt":"2021-01-20T12:03:25","slug":"actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\/","title":{"rendered":"Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n NEW YORK<\/span>, Jan. 20, 2021<\/span> \/PRNewswire\/ — Actinium Pharmaceuticals, Inc.<\/b>\u00a0 (NYSE AMERICAN: ATNM) (“Actinium”) today announced that members of its executive team will participate in a fireside chat at the B. Riley Oncology Investor Conference, which is being held virtually from January 20<\/span>th<\/sup> to 21st<\/sup>. \u00a0During the event, Sandesh Seth<\/span>, Actinium’s Chairman and CEO, Dr. Mark Berger<\/span>, Chief Medical Officer, and Dr. Dale Ludwig<\/span>, Chief Scientific and Technology Officer will participate in a fireside chat discussion moderated by B. Riley analyst Justin Walsh<\/span>. <\/p>\n

\n

\n
\n \"(PRNewsfoto\/Actinium
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n\n\n\n\n\n\n
\n

\n
\n Fireside Chat Details <\/b>
\n <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n

\n Event:\u00a0\u00a0\u00a0\u00a0\u00a0<\/span>\n <\/p>\n<\/td>\n

\n

\n B. Riley Oncology Investor Conference <\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n

\n Participants:<\/span>\n <\/p>\n<\/td>\n

\n

\n Sandesh Seth, Chairman and CEO, Dr. Mark Berger, Chief Medical Officer, and Dr. Dale Ludwig, Chief Scientific and Technology Officer<\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n

\n Date:<\/span>\n <\/p>\n<\/td>\n

\n

\n Thursday, January 21st<\/sup><\/span>\n <\/p>\n<\/td>\n<\/tr>\n

\n \n <\/td>\n\n

\n Time:<\/span>\n <\/p>\n<\/td>\n

\n

\n 3:30 p.m. ET<\/span>\n <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n

In addition, members of the executive team will be available for one-on-one meetings with conference attendees. \u00a0Those interested in scheduling a meeting may do so by contacting their B. Riley representative or the Company at investorrelations@actiniumpharma.com<\/a>.\u00a0\u00a0<\/p>\n

\n About Actinium Pharmaceuticals, Inc. (NYSE: ATNM)<\/b>\n <\/p>\n

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing ARCs or Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation.\u00a0 Actinium’s lead application for our ARCs is targeted conditioning, which is intended to selectively deplete a patient’s disease or cancer cells and certain immune cells prior to a BMT or Bone Marrow Transplant, Gene Therapy or Adoptive Cell Therapy (ACT) such as CAR-T to enable engraftment of these transplanted cells with minimal toxicities.\u00a0 With our ARC approach, we seek to improve patient outcomes and access to these potentially curative treatments by eliminating or reducing the non-targeted chemotherapy that is used for conditioning in standard practice currently.\u00a0 Our lead product candidate, I-131 apamistamab (Iomab-B) is being studied in the ongoing pivotal Phase 3 Study of Iomab-B in Elderly Relapsed or Refractory Acute Myeloid Leukemia (SIERRA) trial for BMT conditioning.\u00a0 The SIERRA trial is over seventy-five percent enrolled and positive single-agent, feasibility and safety data has been highlighted at ASH, TCT, ASCO and SOHO annual meetings.\u00a0 More information on this Phase 3 clinical trial can be found at sierratrial.com. I-131 apamistamab will also be studied as a targeted conditioning agent in a Phase 1 study with a CD19 CAR T-cell Therapy and Phase 1\/2 anti-HIV stem cell gene therapy with UC Davis.\u00a0 In addition, we are developing a multi-disease, multi-target pipeline of clinical-stage ARCs targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a broad range of hematologic malignancies including acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma.\u00a0 Ongoing combination trials include our CD33 alpha ARC, Actimab-A, in combination with the salvage chemotherapy CLAG-M and the Bcl-2 targeted therapy venetoclax.\u00a0 Underpinning our clinical programs is our proprietary AWE (Antibody Warhead Enabling) technology platform.\u00a0 This is where our intellectual property portfolio of over 130 patents, know-how, collective research and expertise in the field are being leveraged to construct and study novel ARCs and ARC combinations to bolster our pipeline for strategic purposes.\u00a0 Our AWE technology platform is currently being utilized in a collaborative research partnership with Astellas Pharma, Inc. Website: https:\/\/www.actiniumpharma.com\/<\/a><\/p>\n

\n Contacts:<\/b>\n <\/p>\n

Investors:
Clayton Robertson<\/span>
Actinium Pharmaceuticals, Inc.
crobertson@actiniumpharma.com<\/a><\/u><\/p>\n

\n Hans Vitzthum<\/span>
\n
LifeSci Advisors, LLC
Hans@LifeSciAdvisors.com<\/a>
(617) 430-7578<\/p>\n

\u00a0<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference-301211474.html<\/a><\/p>\n

SOURCE Actinium Pharmaceuticals, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire NEW YORK, Jan. 20, 2021 \/PRNewswire\/ — Actinium Pharmaceuticals, Inc.\u00a0 (NYSE AMERICAN: ATNM) (“Actinium”) today announced that members of its executive team will participate in a fireside chat at the B. Riley Oncology Investor Conference, which is being held virtually from January 20th to 21st. \u00a0During the event, Sandesh Seth, Actinium’s Chairman and CEO, Dr. Mark Berger, Chief Medical Officer, and Dr. Dale Ludwig, Chief Scientific and Technology Officer will participate in a fireside chat discussion moderated by B. Riley analyst Justin Walsh. Fireside Chat Details Event:\u00a0\u00a0\u00a0\u00a0\u00a0 B. Riley Oncology Investor Conference Participants: Sandesh Seth, Chairman and CEO, Dr. Mark Berger, Chief Medical Officer, and Dr. Dale Ludwig, Chief Scientific and Technology Officer Date: Thursday, January 21st Time: … <\/p>\n

Continue reading “Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-417619","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nActinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW YORK, Jan. 20, 2021 \/PRNewswire\/ — Actinium Pharmaceuticals, Inc.\u00a0 (NYSE AMERICAN: ATNM) (“Actinium”) today announced that members of its executive team will participate in a fireside chat at the B. Riley Oncology Investor Conference, which is being held virtually from January 20th to 21st. \u00a0During the event, Sandesh Seth, Actinium’s Chairman and CEO, Dr. Mark Berger, Chief Medical Officer, and Dr. Dale Ludwig, Chief Scientific and Technology Officer will participate in a fireside chat discussion moderated by B. Riley analyst Justin Walsh. Fireside Chat Details Event:\u00a0\u00a0\u00a0\u00a0\u00a0 B. Riley Oncology Investor Conference Participants: Sandesh Seth, Chairman and CEO, Dr. Mark Berger, Chief Medical Officer, and Dr. Dale Ludwig, Chief Scientific and Technology Officer Date: Thursday, January 21st Time: … Continue reading "Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-20T12:03:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/730678\/Actinium_Pharmaceuticals_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference\",\"datePublished\":\"2021-01-20T12:03:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\\\/\"},\"wordCount\":578,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/730678\\\/Actinium_Pharmaceuticals_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\\\/\",\"name\":\"Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/730678\\\/Actinium_Pharmaceuticals_Logo.jpg\",\"datePublished\":\"2021-01-20T12:03:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/730678\\\/Actinium_Pharmaceuticals_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/730678\\\/Actinium_Pharmaceuticals_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\/","og_locale":"en_US","og_type":"article","og_title":"Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference - Market Newsdesk","og_description":"PR Newswire NEW YORK, Jan. 20, 2021 \/PRNewswire\/ — Actinium Pharmaceuticals, Inc.\u00a0 (NYSE AMERICAN: ATNM) (“Actinium”) today announced that members of its executive team will participate in a fireside chat at the B. Riley Oncology Investor Conference, which is being held virtually from January 20th to 21st. \u00a0During the event, Sandesh Seth, Actinium’s Chairman and CEO, Dr. Mark Berger, Chief Medical Officer, and Dr. Dale Ludwig, Chief Scientific and Technology Officer will participate in a fireside chat discussion moderated by B. Riley analyst Justin Walsh. Fireside Chat Details Event:\u00a0\u00a0\u00a0\u00a0\u00a0 B. Riley Oncology Investor Conference Participants: Sandesh Seth, Chairman and CEO, Dr. Mark Berger, Chief Medical Officer, and Dr. Dale Ludwig, Chief Scientific and Technology Officer Date: Thursday, January 21st Time: … Continue reading \"Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-20T12:03:25+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/730678\/Actinium_Pharmaceuticals_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference","datePublished":"2021-01-20T12:03:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\/"},"wordCount":578,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/730678\/Actinium_Pharmaceuticals_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\/","name":"Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/730678\/Actinium_Pharmaceuticals_Logo.jpg","datePublished":"2021-01-20T12:03:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/730678\/Actinium_Pharmaceuticals_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/730678\/Actinium_Pharmaceuticals_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/actinium-to-participate-in-a-fireside-chat-at-the-b-riley-oncology-investor-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Actinium to Participate in a Fireside Chat at the B. Riley Oncology Investor Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/417619","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=417619"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/417619\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=417619"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=417619"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=417619"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}